✦ LIBER ✦

Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site : A phase 2 trial of the Sarah Cannon Oncology Research Consortium

✍ Scribed by John D. Hainsworth; David R. Spigel; Howard A. Burris III; Dianna Shipley; Cindy Farley; Ines M. Macias-Perez; John Barton; F. Anthony Greco

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 156 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab and everolimus in the treatm

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma : A phase 2 trial of the Sarah Cannon Oncology Research Consortium

✍ John D. Hainsworth; Jeffrey R. Infante; David R. Spigel; James D. Peyton; Dana S 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 1 views

Weekly treatment with bortezomib for pat

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; David R. Spigel; John Barton; Cindy Farley; Marshall Schreed 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

## Abstract ## BACKGROUND. The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma. ## METHODS. A total of 40 patients with multiple myeloma who had received either 1 or 2 previous tre

A phase 2 trial of bortezomib followed b

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303)

✍ Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S. Axelrod; Ron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 1 views

## Abstract ## BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. ## METHODS: Eligibility criteria included incurable ACC, any number of pr

A phase II study of 5-fluorouracil, leuc

A phase II study of 5-fluorouracil, leucovorin, and interferon-α in the treatment of patients with metastatic or recurrent gastric carcinoma : An Eastern Cooperative Oncology Group study (E5292)

✍ Gary R. Hudes; Stuart Lipsitz; Jean Grem; Mary Morrisey; Louis Weiner; John W. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

Chemotherapy has a limited impact on adenocarcinoma of the stomach. Although biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) and interferon-␣ (IFN-␣) has improved the outcomes of patients with metastatic colorectal carcinoma compared with 5-FU alone, this approach has not been ext

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO